4.7 Article

Prevention of Ulcerative Colitis by Autologous Metabolite Transfer from Colitogenic Microbiota Treated with Lipid Nanoparticles Encapsulating an Anti-Inflammatory Drug Candidate

Journal

PHARMACEUTICS
Volume 14, Issue 6, Pages -

Publisher

MDPI
DOI: 10.3390/pharmaceutics14061233

Keywords

natural-lipid nanoparticles; M13; ex vivo culture; microbiota-secreted metabolites; IL-10 knockout; chronic inflammation

Funding

  1. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [RO1-DK-116306, RO1-DK-107739]
  2. Department of Veterans Affairs [BX004476, BX002526]
  3. Crohn's and Colitis Foundation (CCF) [689659]

Ask authors/readers for more resources

Modulating gut microbiota composition is an effective approach for treating chronic diseases, but current methods carry the risk of transmitting multi-drug-resistant organisms. In this study, an organism-free strategy was developed to modulate gut microbiota ex vivo and transfer microbiota-secreted metabolites back to the host, and it was found to effectively prevent chronic ulcerative colitis.
Modulating the gut microbiota composition is a potent approach to treat various chronic diseases, including obesity, metabolic syndrome, and ulcerative colitis (UC). However, the current methods, such as fecal microbiota transplantation, carry a risk of serious infections due to the transmission of multi-drug-resistant organisms. Here, we developed an organism-free strategy in which the gut microbiota is modulated ex vivo and microbiota-secreted metabolites are transferred back to the host. Using feces collected from the interleukin-10 (IL-10) knockout mouse model of chronic UC, we found that a drug candidate (M13)-loaded natural-lipid nanoparticle (M13/nLNP) modified the composition of the ex vivo-cultured inflamed gut microbiota and its secreted metabolites. Principal coordinate analysis (PCoA) showed that M13/nLNP shifted the inflamed microbiota composition toward the non-inflamed direction. This compositional modification induced significant changes in the chemical profiles of secreted metabolites, which proved to be anti-inflammatory against in vitro-cultured NF-kappa beta reporter cells. Further, when these metabolites were orally administered to mice, they established strong protection against the formation of chronic inflammation. Our study demonstrates that ex vivo modulation of microbiota using M13/nLNP effectively reshaped the microbial secreted metabolites and that oral transfer of these metabolites might be an effective and safe therapeutic approach for preventing chronic UC.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available